The Thyroid Beyond TSH: Why Normal Results Leave Patients Undiagnosed

Thyroid Physiology: A Cascade, Not a Single Signal

The thyroid gland does not operate in isolation. It is the end-effector of a three-tier hypothalamic-pituitary-thyroid (HPT) axis, each layer subject to its own regulatory inputs, feedback loops, and points of potential failure. Understanding this architecture is the prerequisite for understanding why TSH, measured at the middle tier, provides an incomplete picture of what is happening at the cellular level where thyroid hormones do their work.

The cascade begins in the hypothalamus, where thyrotropin-releasing hormone (TRH) is synthesised and secreted into the hypothalamic-pituitary portal circulation in a pulsatile fashion. TRH acts on thyrotrophs in the anterior pituitary to stimulate the synthesis and release of thyroid-stimulating hormone (TSH). TSH, a glycoprotein of approximately 28 kDa, then binds its receptor on thyroid follicular cells, driving the synthesis and secretion of thyroxine (T4) and, to a lesser degree, triiodothyronine (T3) [1].

Critically, approximately 80% of circulating T3 — the biologically active form of thyroid hormone — is not secreted directly by the thyroid gland. It is produced peripherally through the enzymatic removal of a single iodine atom from the outer ring of T4, a process catalysed by the deiodinase enzyme family [2]. T4 is therefore best understood as a prohormone: a circulating reservoir from which active T3 is extracted on demand, in a tissue-specific and context-sensitive manner.

T3 exerts its effects by binding to nuclear thyroid hormone receptors (TRα and TRβ), modulating the transcription of genes governing virtually every metabolic pathway in the body — from mitochondrial biogenesis and basal metabolic rate to cardiac contractility, neurological function, gut motility, hair follicle cycling, and bone mineral metabolism [1]. This breadth of action explains why thyroid dysfunction, even when subtle, generates symptoms across every organ system.

Why TSH Alone Is Insufficient

TSH is an excellent marker of pituitary function. It reflects the anterior pituitary's assessment of circulating free T4 levels via negative feedback. When T4 rises, TSH falls; when T4 drops, TSH rises. This feedback loop is elegantly sensitive — TSH can detect changes in free T4 as small as 0.01–0.02 ng/dL — and for this reason it became the cornerstone of thyroid screening [1].

However, the logical leap from "TSH is a sensitive marker of T4 availability at the pituitary" to "TSH tells us everything we need to know about thyroid function throughout the body" is a leap that the physiology does not support. There are at least four distinct mechanisms by which clinically significant thyroid dysfunction can exist in the setting of a normal TSH.

1. Impaired T4 to T3 Conversion

If T4 is being produced normally by the thyroid gland and sensed normally by the pituitary — yielding a normal TSH — but peripheral deiodinase activity is impaired, the cells of the brain, liver, gut, and skeletal muscle will be T3-deficient despite a perfectly normal TSH. The pituitary, satisfied by adequate T4, sends no alarm signal. The patient experiences fatigue, cognitive slowing, cold intolerance, constipation, and weight gain — all the hallmarks of hypothyroidism — and is told their thyroid is fine [3].

2. Reverse T3 Dominance

Under conditions of physiological stress — whether from infection, caloric restriction, cortisol excess, or systemic inflammation — the deiodinase system is redirected. Instead of converting T4 to active T3, the enzyme DIO3 preferentially converts T4 to reverse T3 (rT3), a structurally identical but metabolically inert molecule that occupies T3 receptor binding sites without activating them [2]. The net effect is functional hypothyroidism at the cellular level in the presence of normal TSH and even normal free T4.

3. Central Hypothyroidism

In pituitary or hypothalamic dysfunction, TSH secretion may be reduced or dysregulated such that TSH falls within the normal range even as T4 and T3 are genuinely low. This form of "central hypothyroidism," while less common than primary thyroid disease, is another clinical scenario in which relying on TSH alone leads to missed diagnosis [4].

4. Autoimmune Thyroid Dysfunction Prior to TSH Abnormality

Hashimoto's thyroiditis — the autoimmune destruction of thyroid tissue — may be active for years, with progressive loss of follicular architecture, before thyroid reserve is sufficiently depleted to cause TSH elevation. During this period, antibody positivity (elevated TPOAb or TgAb) identifies patients at high risk who are symptomatic and warrant intervention, yet TSH remains ostensibly normal [5].

The Full Thyroid Cascade: What Each Marker Tells Us

A comprehensive thyroid assessment is not a luxury panel. It is the minimum scientific standard for evaluating thyroid function with any degree of clinical accuracy. The following markers constitute what I consider the standard-of-care thyroid cascade at Longyx.

Thyroid-Stimulating Hormone (TSH)

TSH remains the most sensitive initial screening marker for primary thyroid disease and for monitoring thyroid hormone replacement therapy. Its limitations lie not in its analytical sensitivity but in its specificity for cellular thyroid hormone status. An isolated TSH cannot distinguish between adequate T3 delivery to peripheral tissues, impaired conversion, rT3 dominance, or autoimmune inflammation. It is the beginning of thyroid assessment, not the end.

Free Thyroxine (Free T4)

Free T4 represents the unbound, biologically available fraction of thyroxine in circulation, distinguishable from protein-bound T4 which is metabolically inactive. Low free T4 with elevated TSH confirms primary hypothyroidism. Low free T4 with normal or low TSH raises suspicion of central hypothyroidism. Normal free T4 with ongoing symptoms directs investigation toward conversion and receptor-level dysfunction.

Free Triiodothyronine (Free T3)

Free T3 is the most metabolically active thyroid hormone and the proximate driver of nuclear receptor signalling. Low free T3 in the setting of normal TSH and free T4 is a direct indicator of impaired peripheral conversion — the precise scenario that routine testing misses entirely. Jonklaas et al. demonstrated that a subset of patients on T4-only replacement therapy continue to exhibit low free T3 and persistent symptoms, responding only to combination T4/T3 treatment — evidence that conversion efficiency varies between individuals in clinically meaningful ways [3].

Reverse T3 (rT3)

Reverse T3 is the metabolically inactive isomer of T3, produced when T4 undergoes inner-ring deiodination by DIO3 rather than the outer-ring deiodination that yields active T3. In states of physiological stress, rT3 production is upregulated as part of a conserved adaptive response to reduce metabolic expenditure — the "low T3 syndrome" observed in critical illness and starvation [2]. The rT3:free T3 ratio provides a practical clinical index of this imbalance. An elevated rT3 with low or low-normal free T3 and a normal TSH is among the most commonly encountered patterns in fatigued, hormonally dysregulated patients in functional medicine practice — and among the most consistently overlooked in conventional settings.

Thyroid Peroxidase Antibodies (TPOAb)

Thyroid peroxidase is the enzyme responsible for the oxidation of iodide and the iodination of thyroglobulin during T4 synthesis. TPO antibodies are the hallmark of Hashimoto's thyroiditis and are elevated in approximately 90–95% of patients with the condition. Their presence, even in the setting of normal TSH and free hormones, identifies a patient with active thyroid autoimmunity who is on a trajectory toward clinical hypothyroidism and who warrants therapeutic and lifestyle intervention now, not at the point of TSH abnormality [5].

Thyroglobulin Antibodies (TgAb)

Thyroglobulin antibodies target the protein scaffold on which thyroid hormones are synthesised. Elevated TgAb may be present in Hashimoto's patients who are TPOAb-negative, and testing both antibodies increases diagnostic sensitivity for autoimmune thyroid disease. In post-thyroidectomy or post-ablation patients, TgAb can also interfere with thyroglobulin tumour marker assays — a clinically important artefact to recognise.

Subclinical Hypothyroidism: The Grey Zone Nobody Talks About

Subclinical hypothyroidism (SCH) is conventionally defined as a TSH above the upper limit of the reference range (typically 4.5 mIU/L) with normal free T4. But this definition creates an artificial cliff: the patient with a TSH of 4.4 mIU/L is told they are normal, while the patient at 4.6 mIU/L receives a diagnosis. Clinically, physiologically, and symptomatically, this boundary is arbitrary.

Surks and colleagues, in their landmark JAMA analysis, established that TSH reference ranges are themselves population-derived statistical constructs that include a proportion of individuals with subclinical thyroid disease [6]. When individuals with detectable thyroid antibodies are excluded from reference population calculations, the upper limit of a truly euthyroid TSH distribution falls closer to 2.5 mIU/L [6]. This finding has profound implications: the conventional upper limit of 4.5 mIU/L may include a substantial number of individuals with mild but clinically significant thyroid impairment.

The symptomatic burden of TSH values in the 2.5–4.5 mIU/L range — what I call the grey zone — is increasingly well-documented. Fatigue, cold sensitivity, brain fog, weight resistance, menstrual irregularity, hair thinning, and low mood are the most commonly reported symptoms in this population. These patients are often investigated for depression, anaemia, perimenopause, or chronic fatigue syndrome, receiving treatment for downstream effects while the upstream hormonal driver remains unaddressed.

From a cardiovascular standpoint, even subclinical hypothyroidism in the TSH 4.5–10.0 mIU/L range is associated with an increased risk of coronary heart disease events and mortality in younger patients, particularly those under 65, as demonstrated in a large meta-analysis [4]. The extension of this risk into the grey zone of TSH 2.5–4.5 is an area of active investigation — and a compelling reason for clinical vigilance rather than reassurance.

Reverse T3 Dominance: The Metabolic Brake

The concept of reverse T3 dominance remains under-taught in conventional medical training, yet it is one of the most clinically prevalent explanations for persistent hypothyroid symptoms in patients with normal standard thyroid panels. Understanding it requires revisiting the deiodinase system.

T4 has two possible metabolic fates: outer-ring deiodination to active T3 (catalysed primarily by DIO1 and DIO2), or inner-ring deiodination to reverse T3 (catalysed primarily by DIO3). These two pathways are in dynamic competition, and their relative activity is exquisitely sensitive to systemic state. Bianco et al. provide a comprehensive mechanistic review of deiodinase regulation, demonstrating that physiological stressors — elevated cortisol, interleukin-6, tumour necrosis factor-alpha, and reduced selenoprotein availability — all shift the balance toward DIO3 activity and rT3 production [2].

The clinical conditions most strongly associated with elevated rT3 include:

• Chronic psychological stress and HPA axis dysregulation (elevated cortisol shifts deiodinase balance toward rT3)
• Caloric restriction and low-carbohydrate dietary protocols (an adaptive reduction in metabolic rate)
• Acute and chronic illness, particularly systemic inflammatory conditions
• Selenium deficiency (deiodinase enzymes are selenoproteins; inadequate selenium impairs DIO1 and DIO2 function)
• Elevated ferritin states and iron dysregulation
• Exogenous T4 therapy without T3 co-administration

Reverse T3 itself is not merely an inactive metabolite — it actively competes with T3 for binding to nuclear thyroid hormone receptors, particularly TRβ. Elevated rT3 therefore exerts a competitive inhibitory effect on T3 signalling, reducing cellular thyroid hormone sensitivity even when free T3 is technically within range. The net clinical picture is one of functional hypothyroidism: normal TSH, normal or borderline free T4, free T3 in the lower range, rT3 elevated, and a patient reporting every symptom in the hypothyroid catalogue [2].

This is not a theoretical construct. It is a pattern I see with remarkable consistency in women presenting with fatigue, metabolic resistance, and post-infectious or post-stress functional decline. The critical diagnostic step is to measure it.

Deiodinase Genetics: Why Two Patients with Identical TSH Can Feel Completely Different

Perhaps the most compelling scientific argument against TSH-only thyroid assessment comes from the genomics of thyroid hormone metabolism. The deiodinase enzymes — DIO1, DIO2, and DIO3 — are not identical in all individuals. They are encoded by genes that exhibit clinically significant polymorphism, and these genetic variants directly determine how efficiently any given person converts T4 to T3.

Bianco et al. conducted an extensive characterisation of deiodinase isoforms, demonstrating that DIO2, primarily responsible for T4-to-T3 conversion in the central nervous system, pituitary, cardiac muscle, and brown adipose tissue, is especially subject to functional genetic variation [2]. The DIO2 Thr92Ala polymorphism (rs225014) — a threonine-to-alanine substitution at codon 92 — has been identified as the most clinically relevant. Carriers of the Ala/Ala genotype demonstrate impaired T4-to-T3 conversion in brain and pituitary tissue, with consequent reduced intracellular T3 availability in these organs despite normal circulating hormone levels.

Werneck de Castro et al. provided direct experimental evidence for the clinical significance of this variant. In a study of hypothyroid patients on T4 monotherapy, Ala/Ala homozygotes showed persistently worse cognitive and psychological test performance compared to Thr/Thr carriers — despite identical TSH values — and experienced clinically meaningful improvement when switched to combination T4/T3 therapy [7]. This finding has profound therapeutic implications: it means that for a significant proportion of patients (the Ala92 variant has an allele frequency of approximately 36% in European populations), T4-only replacement therapy is constitutionally inadequate, not because the dose is wrong, but because the conversion machinery is genetically limited.

DIO1 genetic variants similarly affect peripheral T4-to-T3 conversion and have been associated with altered T3:T4 ratios in population studies. DIO3 variants influence the clearance of both T3 and rT3, potentially contributing to inter-individual variation in rT3 accumulation under stress conditions [2].

Hashimoto's Thyroiditis: The Autoimmune Architecture

Hashimoto's thyroiditis — also termed chronic lymphocytic thyroiditis or autoimmune thyroiditis — is the most prevalent autoimmune condition in developed nations and the leading cause of hypothyroidism in iodine-sufficient populations. It affects approximately 5% of the general population, with a female-to-male ratio of 7:1 to 10:1, and its prevalence peaks in the third to fifth decades of life [1]. Given this epidemiology, it is not hyperbolic to state that Hashimoto's is the most important condition to identify in women presenting with unexplained fatigue, weight gain, or mood disturbance.

The pathophysiology centres on a loss of immunological tolerance to thyroid antigens — principally thyroid peroxidase and thyroglobulin. Autoreactive CD4+ T helper cells infiltrate the thyroid gland, orchestrating a mixed Th1/Th17 immune response that results in lymphocytic infiltration, follicular destruction, and progressive replacement of functional thyroid tissue with fibrous stroma. B cells produce TPOAb and TgAb, which are pathologically meaningful markers of this process and clinically detectable years before structural or functional changes appear on routine testing [5].

The Gut–Thyroid Axis

Growing evidence implicates intestinal permeability and gut microbiome dysbiosis as upstream drivers of Hashimoto's autoimmunity. The gut epithelium acts as the primary barrier between environmental antigens and the systemic immune compartment. When tight junction integrity is compromised — by gluten, lipopolysaccharides from gram-negative bacteria, stress, or non-steroidal anti-inflammatory drugs — luminal antigens gain access to lamina propria immune cells, triggering systemic inflammatory and autoimmune cascades.

Molecular mimicry is the proposed mechanism linking intestinal antigen exposure to thyroid autoimmunity. Gliadin peptides — derived from gluten — bear structural homology to thyroid antigens. In genetically susceptible individuals, the immune response mounted against gliadin epitopes may cross-react with thyroid peroxidase, generating the sustained antibody production that characterises Hashimoto's [5]. The clinical evidence for a gluten–Hashimoto's connection is sufficiently robust that a trial of strict gluten elimination is now a reasonable first-line intervention in TPOAb-positive patients, regardless of coeliac serology.

The gut microbiome additionally regulates thyroid function through two further mechanisms: intestinal deiodinase activity (gut bacteria contribute meaningfully to peripheral T3 production) and iodine-thyroid axis modulation via microbial iodine uptake and excretion. Dysbiosis therefore undermines thyroid function both immunologically and metabolically.

Antibody Positivity as an Actionable Finding

Elevated TPOAb or TgAb in the context of normal TSH and free hormones is not a "wait and see" result. It is an active autoimmune process that warrants therapeutic engagement. Studies demonstrate that selenium supplementation (200 mcg selenomethionine daily) significantly reduces TPOAb titres and may attenuate progression to clinical hypothyroidism [2]. This is mechanistically coherent: selenoproteins include both the deiodinase enzymes and thioredoxin reductases involved in managing oxidative stress within thyroid follicular cells. Selenium is, in this sense, the nutrient at the crossroads of conversion and autoimmunity.

The Optimal TSH Debate: 0.5–2.0 vs. 0.4–4.5

The laboratory reference range for TSH of 0.4–4.5 mIU/L was established through cross-sectional population surveys conducted in the 1970s and 1980s. These ranges were calculated statistically — as the central 95th percentile of values observed in populations assumed to be euthyroid. Critically, many of the individuals included in these reference populations harboured subclinical thyroid disease, most notably undetected Hashimoto's thyroiditis with early antibody positivity [6].

Surks et al., analysing NHANES III data, found that the TSH distribution in the reference population is right-skewed — with a geometric mean of approximately 1.4 mIU/L — and that a disproportionate number of values in the 2.5–4.5 mIU/L range come from individuals with positive thyroid antibodies [6]. When the antibody-positive subjects are excluded, the "truly euthyroid" TSH distribution is substantially tighter, supporting an upper functional limit closer to 2.5 mIU/L.

The Garber et al. hypothyroidism management guidelines from the American Thyroid Association acknowledge this complexity, noting that the appropriate TSH target during treatment should be individualised, with many clinicians targeting 1.0–2.5 mIU/L in symptomatic patients who have previously felt well at lower TSH levels [4]. The ATA guidelines further recognise that blanket population-level reference ranges may not be appropriate for all clinical circumstances, including pregnancy, the elderly, and patients on levothyroxine therapy [4].

From a longevity medicine perspective, the question is not merely "what TSH is not overtly hypothyroid?" but "what TSH is associated with optimal metabolic function, cognitive performance, cardiovascular health, and quality of life?" These are distinct questions, and the answer to the second appears to lie in the lower half of the conventional reference range. Observational data from population studies consistently show that the lowest all-cause mortality risk is associated with TSH values between 0.5 and 2.0 mIU/L — not 0.4–4.5 mIU/L.

What to Do with the Findings: Clinical Protocols

When the full cascade reveals thyroid dysfunction invisible to TSH alone, the clinical response is proportionate to the mechanism identified. Below are the primary intervention frameworks I use in practice.

Selenium Repletion

Given selenium's role as the essential cofactor for all three deiodinase enzymes and its anti-inflammatory effect on thyroid follicular cells, selenium assessment and repletion is a universal starting point. The target is selenomethionine at 100–200 mcg daily, guided by serum selenium status and adjusted to avoid toxicity (the therapeutic window is narrow — selenium excess is itself harmful). In antibody-positive patients, selenium supplementation is additionally supported by randomised controlled trial data showing significant reductions in TPOAb titres [2].

Gut Integrity and Dietary Modification

In Hashimoto's patients, a structured elimination protocol — removing gluten, dairy, and processed soy as a minimum — constitutes a first-line immunological intervention. Alongside this, gut barrier repair with targeted nutraceuticals (zinc carnosine, L-glutamine, butyrate, and specific probiotic strains associated with immune regulation) addresses the upstream driver of ongoing autoimmunity [5].

Addressing the Cortisol–rT3 Relationship

Where elevated rT3 is driven by HPA axis dysregulation and chronic stress, the deiodinase imbalance will not resolve with thyroid-targeted treatment alone. Cortisol normalisation — through adaptogen protocols, sleep architecture optimisation, and structured stress reduction — is a prerequisite for restoring favourable T4-to-T3 conversion. This is systems medicine in its most literal sense: the thyroid axis cannot be treated in isolation from the adrenal axis.

Combination T4/T3 Therapy

For patients with confirmed conversion impairment — particularly those with DIO2 Thr92Ala variant, elevated rT3, low free T3, and persistent symptoms on T4 monotherapy — combination therapy with both T4 (levothyroxine) and T3 (liothyronine, or desiccated thyroid extract) is a clinically justified and evidence-supported option. The Jonklaas et al. ATA task force review and the Werneck de Castro mechanistic study both support a personalised approach to hormone replacement that considers individual conversion capacity [3,7].

Micronutrient Optimisation

Beyond selenium, thyroid function requires adequate iodine (the substrate for T4 synthesis), iron (essential for thyroid peroxidase catalytic activity), zinc (required for T3 nuclear receptor binding), vitamin D (modulates immune tolerance and may attenuate autoimmune progression), and magnesium (involved in TRH receptor signalling). Comprehensive micronutrient assessment is therefore a standard component of thyroid management in functional and longevity medicine practice.

The Longyx Approach: Standard-of-Care Redefined

At Longyx, we do not offer the full thyroid cascade as a premium add-on or an integrative upgrade. We offer it as the baseline — the minimum clinically defensible standard for thyroid assessment in any patient presenting with fatigue, metabolic dysregulation, hormonal imbalance, cognitive symptoms, or mood disturbance. Because these are, to a significant degree, thyroid symptoms. And thyroid symptoms require a complete thyroid assessment.

Every new patient at Longyx receives TSH, free T4, free T3, reverse T3, TPOAb, and TgAb as part of their initial comprehensive bloodwork. This is not driven by a desire to find pathology where none exists. It is driven by the recognition that conventional testing reliably misses a clinically significant proportion of thyroid dysfunction — and that the consequences of that missed diagnosis, measured in years of unnecessary suffering, misattributed symptoms, and downstream metabolic and cardiovascular disease, are unacceptable when the solution is a six-marker panel.

When the full cascade is interpreted through the lens of optimal functional ranges — TSH 0.5–2.0 mIU/L, free T3 in the upper quartile, rT3:free T3 ratio below 20, antibodies ideally below detectable thresholds — we are asking a fundamentally different question than the one conventional medicine asks. We are not asking "does this patient have thyroid disease?" We are asking "is this patient's thyroid function supporting the expression of their full biological potential?" These questions have different answers far more often than the current diagnostic framework acknowledges.

Conclusion

The thyroid gland is not a TSH-responsive switch. It is a dynamic, multistep endocrine system embedded in a web of immune, nutritional, genetic, and neuroendocrine inputs, each capable of disrupting the translation of pituitary signals into cellular thyroid hormone availability. TSH, for all its analytical elegance, captures only one signal in this web — and it captures it at the second step of a five-step cascade.

The scientific literature reviewed here — spanning deiodinase biochemistry, genetic pharmacogenomics, autoimmune pathophysiology, and population epidemiology — converges on a single clinical conclusion: the routine use of TSH as a sole thyroid biomarker is not a defensible standard of care in patients with thyroid-related symptoms. Free T3, free T4, reverse T3, TPOAb, and TgAb are not specialised tests. They are fundamental data points without which thyroid assessment is structurally incomplete.

The patients who benefit most from this expanded paradigm are also those most likely to be underserved by conventional medicine: women in the third to fifth decades of life with fatigue, metabolic resistance, cognitive symptoms, or mood disturbance attributed to stress, ageing, or psychosocial factors. For these patients, a complete thyroid cascade is not an academic exercise. It is the difference between a diagnosis and a decade of unnecessary suffering.

At Longyx, this is not an aspiration. It is our standard protocol — because precision medicine begins with precise measurement.